Kineret (anakinra), a new biotech drug for rheumatoid arthritis

February 2002

Amgen is now launching Kineret (anakinra), a new biotech drug for rheumatoid arthritis.

It's the first interleukin-1 (IL-1) receptor antagonist.

Blocking this protein reduces joint pain and inflammation...and might slow the progression of the disease.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

ibuprofen might reduce the benefit of taking low-dose aspirin
Dermatology new OTC Lotrimin that DOESN'T contain clotrimazole
Dermatology A hubbub is brewing over the OTC analgesic lotion Joint-Ritis
Dermatology Solaraze, a new topical gel for actinic keratoses
Hematology & Oncology Arimidex (anastrozole) is more effective than tamoxifen for EARLY breast cancer
Cardiology Advicor, the first combo drug for dyslipidemia
Cardiology whether to treat patients with "white-coat hypertension"
Infectious Diseases single-dose or three-day regimens of Zithromax (azithromycin) for acute otitis media in children
frequent use of triptans can actually EXACERBATE migraines
whether vitamin A causes hip fractures
ginkgo can cause seizures
Kineret (anakinra), a new biotech drug for rheumatoid arthritis
Women's Health women ask if they can insert their birth control pill VAGINALLY
Women's Health whether antibiotics reduce the efficacy of oral contraceptives
Now that Claritin is going off patent, Schering is coming out with Clarinex
Alzheimer's Disease NSAIDs reduce the risk of Alzheimer's
Hematology & Oncology triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer
Practice chart of new drugs approved by the FDA in 2001